NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
This grant supports small businesses conducting clinical trials for NINDS-related products previously funded by NIH SBIR/STTR Phase II awards.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health (NIH)
Due Dates: November 17, 2025
Funding Amounts: Award amount varies; typically matches or is exceeded by third-party investment; project period up to 3 years.
Summary: Supports small businesses previously funded by NIH SBIR/STTR Phase II to conduct clinical trials or research focused on neurological disorders, facilitating commercialization through third-party partnerships.
Key Information: Applicants must secure or anticipate independent third-party funding equal to or greater than the NIH request.
Description
This opportunity provides additional funding to Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II awardees to support clinical trials and clinical research projects that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to help bridge the gap between Phase II research and product commercialization, particularly for capital-intensive clinical trials. Eligible projects may involve drugs, biologics, devices, diagnostics, or therapies (surgical, behavioral, or rehabilitation) targeting neurological disorders. The initiative emphasizes the importance of partnerships with third-party investors or strategic partners, requiring applicants to submit a detailed Commercialization Plan and secure independent third-party investment at least equal to the NIH funding requested.
